# US Minimal Residual Disease Testing Market > US Minimal Residual Disease Testing Market Research Report: Size, Share, Trend Analysis By Technology (Flow Cytometry, Polymerase Chain Reaction (PCR), Next-generation Sequencing (NGS), Others), By Applications (Lymphoma, Leukemia, Solid Tumors, Others) and By End Users (Hospitals & Clinics, Diagnostic Laboratories, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 11.36% - **2024:** $ 507.48 Million - **2025:** $ 565.13 Million - **2035:** $ 1,657.77 Million - **Key Players:** Roche Diagnostics (CH), Abbott Laboratories (US), Thermo Fisher Scientific (US), Qiagen N.V. (NL), Bristol-Myers Squibb (US), Amgen Inc. (US), Illumina Inc. (US), Myriad Genetics Inc. (US) **Report ID:** MRFR/HC/15223-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-minimal-residual-disease-testing-market-16751 --- ## Market Summary ## **US Minimal Residual Disease Testing Market Overview** As per MRFR analysis, the US Minimal Residual Disease Testing Market Size was estimated at 456.36 (USD Million) in 2023. The US Minimal Residual Disease Testing Market Industry is expected to grow from 508.2 (USD Million) in 2024 to 1,658 (USD Million) by 2035. The US Minimal Residual Disease Testing Market CAGR (growth rate) is expected to be around 11.349% during the forecast period (2025 - 2035). ### **Key US Minimal Residual Disease Testing Market Trends Highlighted** The US Minimal Residual Disease (MRD) Testing Market is experiencing significant market trends, driven primarily by the increasing prevalence of hematological malignancies and a growing awareness of the importance of early detection in improving patient outcomes. The FDA's approval of several advanced MRD testing platforms has bolstered confidence in these tools, underscoring their role in personalized medicine. Moreover, the rise of precision oncology is prompting more healthcare providers to incorporate MRD testing into their practice, leading to improved treatment strategies tailored to individual patient needs. Opportunities within the US market include advancements in testing technology and methodologies, such as next-generation sequencing (NGS) and digital PCR, which provide higher sensitivity and specificity in detecting minimal residual disease. There is also a growing interest among pharmaceutical companies to collaborate on MRD testing, as these tests are increasingly seen as critical endpoints in clinical trials, creating a space for innovation and partnerships. Additionally, as healthcare is progressively emphasizing value-based care, the integration of MRD testing into standard practice is likely to improve patient management and reduce treatment costs over time. In recent times, there has been a notable shift towards the accessibility of MRD tests, enabling broader patient populations to benefit from these innovations. Many academic institutions and research hospitals in the US are implementing clinical research studies to further validate and expand the utility of MRD testing in various hematological disorders. As technology continues to evolve and the healthcare landscape shifts towards more personalized treatment approaches, the emphasis on MRD testing will likely continue to rise, making it a crucial component in the management of hematological cancers in the US Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Minimal Residual Disease Testing Market Drivers** ### **Increasing Incidence of Cancer** The rising incidence of cancer in the United States serves as a significant driver for the US Minimal Residual Disease Testing Market Industry. According to the American Cancer Society, an estimated 1.9 million new cancer cases are expected to be diagnosed in 2021, with the incidence projected to increase further by 3% annually through the next decade. This alarming trend underscores the need for advanced diagnostic tools, including minimal residual disease testing, as oncologists and patients increasingly seek methods to monitor treatment response and assess relapses. Established organizations like the National Cancer Institute are continuously updating their statistics and providing resources to support research initiatives aimed at early cancer detection and management. As the demand for accurate monitoring of residual disease post-treatment escalates, investments in innovative testing technologies are expected to increase, propelling market growth significantly. ### **Technological Advancements in Testing Methods** Technological advancements are playing a crucial role in propelling the US Minimal Residual Disease Testing Market Industry forward. The development of more sensitive and specific detection methods, such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques, has revolutionized the diagnostics landscape in the country. According to a report by the Food and Drug Administration (FDA), the approval of numerous NGS tests has surged by over 200% in the last five years, indicating a strong desire for more accurate diagnostics in various medical fields. Companies like Illumina and Thermo Fisher Scientific are at the forefront of this technology, actively developing advanced products that enable early detection of minimal residual disease. These innovations not only provide better outcomes for patients but also attract significant investment from healthcare providers and researchers focusing on cancer therapies. ### **Growing Awareness and Demand for Personalized Medicine** The growing awareness and demand for personalized medicine in the United States significantly influence the US Minimal Residual Disease Testing Market Industry. A survey conducted by the National Institutes of Health found that 88% of physicians believe that personalized medicine improves treatment decisions, with 72% noting that it enhances patient outcomes. This shift towards tailored therapy can be attributed to the increased availability of genomic profiling tests, which can inform how a patient may respond to specific treatments. Organizations such as the Personalized Medicine Coalition are advocating for the integration of these practices in standard healthcare. As healthcare professionals aim to provide targeted therapies, the need for minimal residual disease testing becomes paramount, ensuring that patients receive the most effective treatment while monitoring for any signs of disease recurrences. ## **US Minimal Residual Disease Testing Market Segment Insights** ### **Minimal Residual Disease Testing Market Technology Insights** The Technology segment of the US **[Minimal Residual Disease Testing Market](../../../reports/minimal-residual-disease-testing-market-12590)** has been a critical area of focus over recent years, demonstrating significant advancements and adaptation within the healthcare and diagnostic arenas. This segment comprises various methodologies, including Flow Cytometry, Polymerase Chain Reaction (PCR), and Next-Generation Sequencing (NGS), each providing unique advantages in detecting minimal residual disease, which is pivotal for ensuring better prognostic and therapeutic outcomes in oncology. Flow Cytometry is recognized for its rapid processing capabilities and high precision, allowing clinicians to analyze individual cells based on specific markers. Its ability to provide real-time data makes it a preferred choice in many clinical settings. On the other hand, Polymerase Chain Reaction (PCR) is valued for its sensitivity and specificity in identifying genetic material from even trace levels of disease, which is essential for effective monitoring of cancer recurrence. Furthermore, Next-Generation Sequencing (NGS) has revolutionized the field by offering comprehensive genomic profiling, empowering healthcare providers with deeper insights into the molecular underpinnings of malignancies, thereby significantly enhancing personalized medicine approaches. Other methodologies in this market segment contribute to the diversification of testing options available, ensuring that healthcare professionals can tailor their strategies based on the specific needs and characteristics of their patients. The collective advancements in these technologies underscore a strong trend toward increased accuracy and efficiency in the detection and monitoring of minimal residual disease, further driving advancements in treatment protocols and improving patient outcomes across the US healthcare landscape. As the demand for these technological solutions continues to rise, propelled by ongoing R&D and a growing emphasis on early diagnosis and targeted therapies, the overall potential for growth in this segment remains robust, with continuous innovations expected to enhance the capabilities of minimal residual disease testing methodologies. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Minimal Residual Disease Testing Market Application Insights** The Application segment of the US Minimal Residual Disease Testing Market is pivotal in diagnosing and monitoring various hematological malignancies and solid tumors. Lymphoma and leukemia stand out due to their prevalence and diagnostic complexity, necessitating advanced testing methods that enhance treatment outcomes and patient management. The emphasis on precision medicine drives the growth of these applications, as healthcare providers increasingly seek accurate assessments of residual disease post-treatment. Solid tumors, although diverse, require specific techniques for effective detection of minimal residual disease, underscoring the importance of tailored diagnostic solutions in oncology. Additionally, the 'Others' category captures emerging applications and novel therapies, reflecting the evolving landscape of oncology testing. Overall, the Application segment is characterized by continuous innovation and an increasing focus on personalized treatment approaches, aligning with broader trends in the healthcare industry aimed at improving patient care and outcomes. As the demand for targeted therapies rises, the significance of Minimal Residual Disease Testing expands, fostering advancements in diagnostic technologies and methodologies across the market. ### **Minimal Residual Disease Testing Market End User Insights** The US Minimal Residual Disease Testing Market is evolving significantly, particularly across various end-user segments such as Hospitals and Clinics, Diagnostic Laboratories, and Others. Hospitals and Clinics play a vital role as primary healthcare providers, performing a large volume of testing to monitor patients with hematological malignancies, thus being crucial in identifying minimal residual disease early to guide treatment decisions. Diagnostic Laboratories are instrumental as well, providing specialized testing services and contributing to the accuracy and reliability of minimal residual disease assessments. This segment benefits from advanced technology and a focus on precision medicine, enhancing patient outcomes significantly. The Others segment, which includes various healthcare settings, reflects the diverse applications and increasing awareness of minimal residual disease testing in broader healthcare practices. Overall, the trend towards personalized medicine and the aging population in the US are driving demand across all these segments, while the challenges include regulatory compliance and the need for standardization in testing procedures. Robust developments in research and technology present ample opportunities for growth and innovation within the US Minimal Residual Disease Testing Market. ## **US Minimal Residual Disease Testing Market Key Players and Competitive Insights** The US Minimal Residual Disease Testing Market is characterized by its rapid evolution and growing significance within the healthcare landscape, particularly in oncology. This market is primarily focused on the detection of minimal residual disease, which refers to the small number of cancer cells that may remain in a patient after treatment. The increasing prevalence of cancer and the subsequent demand for effective monitoring solutions have driven innovation and competition among various players. Companies in this market are continually striving to enhance the sensitivity and specificity of their testing methodologies, deploying advanced technologies such as next-generation sequencing and polymerase chain reaction. The competitive dynamics are shaped by factors including product offerings, technological advancements, regulatory approvals, and strategic partnerships, all of which play a crucial role in determining market leadership and operational success in this niche segment of diagnostics. Illumina has established a strong presence in the US Minimal Residual Disease Testing Market, leveraging its expertise in genomic sequencing technologies. The company is well-known for its innovation in next-generation sequencing, which has proven to be pivotal in enhancing the accuracy and efficiency of minimal residual disease detection. Illumina’s strengths lie in its robust research and development capabilities, allowing for continuous advancements in their product lineup. Through strategic collaborations and partnerships with healthcare institutions and research organizations, Illumina is further positioning itself to lead in the evolving landscape of cancer diagnostics. The company's commitment to improving patient outcomes and precision medicine is reflected in its ongoing efforts to provide tools that facilitate more sensitive detection of residual disease, thereby enhancing the monitoring of treatment efficacy. Exact Sciences is another key player in the US Minimal Residual Disease Testing Market, recognized for its focus on cancer detection and precision diagnostics. The company has made significant strides with its innovative products aimed at cancer screening and monitoring, which align well with the growing demand for minimal residual disease testing. Exact Sciences has a portfolio that includes highly sensitive assays designed for various cancer types, enabling clinicians to make informed decisions based on precise data. The company has pursued strategic mergers and acquisitions to enhance its technological capabilities and expand its market reach, which has further solidified its position in the US market. Its commitment to research and development, coupled with a robust commercial strategy, enables Exact Sciences to continuously refine its offerings and effectively meet the needs of healthcare providers and patients navigating the complexities of cancer treatment and monitoring. ### **Key Companies in the US Minimal Residual Disease Testing Market Include** ## **US Minimal Residual Disease Testing Market Industry Developments** The US Minimal Residual Disease Testing Market has seen significant activity recently, with growing recognition of the crucial role these tests play in monitoring cancer treatment effectiveness. Notably, in August 2023, Illumina announced expanded collaborations to enhance genetic testing capabilities, potentially influencing Minimal Residual Disease diagnostics. Similarly, Exact Sciences has made strides in developing more accurate testing methodologies, addressing the demand for precision in cancer care. In November 2022, Abbott Laboratories launched a new blood test geared toward minimal residual disease, which is anticipated to impact patient management decisions significantly. Mergers and acquisitions have also been pivotal, particularly Takeda Pharmaceutical's acquisition of a smaller biotech firm in June 2023, aiming to bolster its testing portfolio related to oncology. The market is benefiting from a substantial valuation growth trend, with major companies like Thermo Fisher Scientific and F. Hoffmann-La Roche investing heavily in Research and Development for advanced testing solutions. Over the past couple of years, from ongoing regulatory approvals to innovative partnerships, the landscape of the US Minimal Residual Disease Testing Market has evolved rapidly, highlighting the importance of continuous advancements in technology and collaboration among industry leaders. ## **US Minimal Residual Disease Testing Market Segmentation Insights** ### **Minimal Residual Disease Testing Market Technology Outlook** ### **Minimal Residual Disease Testing Market Application Outlook** ### **Minimal Residual Disease Testing Market End User Outlook** ## Market Drivers ### Rising Incidence of Cancer The increasing incidence of cancer in the US is a primary driver for the minimal residual-disease-testing market. According to the National Cancer Institute, approximately 1.9 million new cancer cases are expected to be diagnosed in 2025. This surge in cancer cases necessitates advanced diagnostic tools to monitor treatment efficacy and detect residual disease. As healthcare providers seek to improve patient outcomes, the demand for minimal residual disease testing is likely to rise. This market is projected to grow at a CAGR of around 12% from 2025 to 2030, reflecting the urgent need for effective monitoring solutions in oncology. The minimal residual-disease-testing market is thus positioned to expand significantly in response to these trends. ### Advancements in Diagnostic Technologies Technological innovations in diagnostic methodologies are propelling the minimal residual-disease-testing market forward. The introduction of highly sensitive techniques such as next-generation sequencing (NGS) and digital PCR has enhanced the ability to detect minimal residual disease with greater accuracy. These advancements allow for the identification of cancer cells at very low levels, which is crucial for timely intervention. The market for these technologies is expected to reach $2 billion by 2027, driven by their increasing adoption in clinical settings. As healthcare providers aim to implement cutting-edge solutions, the minimal residual-disease-testing market is likely to benefit from these technological advancements, leading to improved patient management and outcomes. ### Increased Investment in Cancer Research The minimal residual-disease-testing market is also being driven by increased investment in cancer research and development. Government funding and private sector investments are focusing on innovative diagnostic solutions that can enhance cancer treatment outcomes. The National Institutes of Health (NIH) has allocated substantial resources towards cancer research, which includes the development of advanced testing methodologies. This financial support is expected to foster innovation within the minimal residual-disease-testing market, leading to the introduction of new products and services. As research progresses, the market is likely to experience a surge in demand for effective testing solutions that can aid in the early detection of residual disease. ### Regulatory Approvals and Reimbursement Policies The evolving landscape of regulatory approvals and reimbursement policies is shaping the minimal residual-disease-testing market. Recent changes in healthcare regulations have streamlined the approval process for new diagnostic tests, making it easier for innovative solutions to enter the market. Additionally, favorable reimbursement policies are encouraging healthcare providers to adopt these tests as part of routine cancer care. As insurance coverage for minimal residual disease testing expands, patient access to these critical diagnostics is likely to improve. This trend is expected to drive market growth, with projections indicating a potential increase in market size by 15% over the next few years. The minimal residual-disease-testing market is thus poised for expansion as regulatory and reimbursement frameworks evolve. ### Growing Awareness Among Healthcare Professionals There is a notable increase in awareness among healthcare professionals regarding the importance of minimal residual disease testing in cancer management. Educational initiatives and clinical guidelines are emphasizing the role of these tests in personalizing treatment plans and improving patient prognoses. As oncologists and hematologists become more informed about the benefits of minimal residual disease testing, the demand for these services is expected to rise. This shift in professional attitudes is likely to contribute to a market growth rate of approximately 10% annually over the next five years. The minimal residual-disease-testing market stands to gain from this heightened awareness, as more practitioners incorporate these tests into standard care protocols. ## Future Outlook The [Minimal Residual Disease Testing Market](https://www.marketresearchfuture.com/reports/minimal-residual-disease-testing-market-12590) is projected to grow at 11.36% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for precision medicine. **New opportunities:** - Development of portable testing devices for remote patient monitoring. Integration of AI algorithms for enhanced diagnostic accuracy. Expansion of partnerships with oncology clinics for comprehensive testing services. By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in precision diagnostics. ## Segment Insights ### By Technology: Flow Cytometry (Largest) vs. Next-generation Sequencing (Fastest-Growing) In the US minimal residual-disease-testing market, Flow Cytometry holds the largest share among technologies, attributed to its widespread adoption in clinical settings for real-time cell analysis. In contrast, Next-generation Sequencing (NGS) is rapidly gaining traction, driven by advancements in genomic technologies and decreasing costs that enhance its accessibility for various medical applications. The growth trends in this segment reflect a shift toward precision medicine and personalized healthcare, where NGS is emerging as a game-changer. Its ability to provide comprehensive genetic insights supports targeted therapy decisions, fostering its popularity. Conversely, Flow Cytometry continues to dominate due to its established methods and reliability, although NGS's rapid advancements position it as a compelling alternative for the future. Technology: Flow Cytometry (Dominant) vs. Next-generation Sequencing (Emerging) Flow Cytometry is characterized by its ability to analyze multiple parameters of individual cells quickly, making it crucial in minimal residual disease detection due to its sensitivity and specificity. It serves as a cornerstone technology in many laboratories due to its established protocols and extensive clinical validation. In comparison, Next-generation Sequencing offers a high-throughput method for sequencing DNA and RNA, providing detailed genetic profiles that aid in understanding disease progression and treatment response. Its emerging status reflects the increasing demand for precision medicine, as healthcare providers strive for more accurate and personalized treatment plans. While Flow Cytometry remains a dominant force, NGS is expected to disrupt the market with its innovative capabilities. ### By Application: Lymphoma (Largest) vs. Leukemia (Fastest-Growing) The market share distribution among the application segments reveals that Lymphoma holds the largest share in the US minimal residual-disease-testing market. It is followed by Leukemia, which is gaining traction due to increasing awareness and advancements in diagnostic technologies. Solid Tumors and Others segments also contribute to the market but occupy relatively smaller shares, reflecting the concentrated focus on blood cancers. Growth trends within this segment indicate a significant upward trajectory for leukemia testing, fueled by innovation in treatment methodologies and heightened clinical adoption. The rising prevalence of hematologic malignancies further enhances demand, while regulatory support for new tests and growing investments in oncology research catalyze market expansion, particularly for the leukemia segment. Lymphoma: Dominant vs. Leukemia: Emerging Lymphoma stands out as the dominant application in the US minimal residual-disease-testing market, characterized by robust testing protocols and established treatment pathways. Its prominence can be attributed to a higher diagnosis rate and effective monitoring capabilities, enabling healthcare providers to strategize treatment effectively. In contrast, the leukemia segment, while emerging, is rapidly expanding due to technological advancements and improved therapeutic options. This segment is witnessing increased investments in R&D, aiming to enhance diagnostic accuracy and treatment personalization. As awareness grows and screening becomes more commonplace, leukemia testing is set to capture a larger portion of the market, creating a competitive dynamic between these two crucial applications. ### By End User: Hospitals & Clinics (Largest) vs. Diagnostic Laboratories (Fastest-Growing) In the US minimal residual-disease-testing market, Hospitals & Clinics command the largest share, playing a pivotal role in diagnostics and patient management. Their extensive reach and established infrastructure enable them to provide comprehensive testing services, which significantly contribute to their market dominance. Diagnostic Laboratories, while smaller in market share, are rapidly gaining traction, driven by their specialized services and ability to offer quick turnaround times. This competitive dynamic drives innovation and efficiency within the sector. The growth trends observed in this segment indicate robust expansion for Diagnostic Laboratories, fueled by increased demand for precise and timely testing solutions. Factors such as technological advancements, increasing funding for healthcare initiatives, and the ongoing focus on personalized medicine are accelerating growth. As healthcare providers strive for better patient outcomes, the reliance on specialized diagnostics is expected to trend upward, positioning Diagnostic Laboratories as a key player in the future landscape of the US minimal residual-disease-testing market. Hospitals & Clinics (Dominant) vs. Diagnostic Laboratories (Emerging) Hospitals & Clinics represent the dominant force in this segment, characterized by their extensive networks and capability to perform a wide range of medical services under one roof. They provide essential minimal residual disease testing and often integrate these services with patient care pathways. This holistic approach not only enhances patient convenience but also promotes timely diagnosis and treatment. In contrast, Diagnostic Laboratories are emerging as significant players by leveraging cutting-edge technologies and specializing in complex testing services. Their agility in adapting to new testing methodologies and the growing demand for rapid results is enabling them to capture a larger market share. The competition between these two segments fosters innovation and drives improvements in diagnostic accuracy and service delivery. ## Competitive Benchmarking The minimal residual-disease-testing market is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing demand for precision medicine. Key players such as Roche Diagnostics (CH), Abbott Laboratories (US), and Thermo Fisher Scientific (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Roche Diagnostics (CH) focuses on innovation through the development of next-generation sequencing technologies, which are pivotal in improving the accuracy of minimal residual disease detection. Meanwhile, Abbott Laboratories (US) emphasizes strategic partnerships with healthcare providers to expand its testing capabilities and reach a broader patient population. Thermo Fisher Scientific (US) is leveraging its extensive portfolio to integrate digital solutions into its testing processes, thereby enhancing operational efficiency and customer engagement. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological advancement and collaborative growth. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence while also allowing for niche entrants. This fragmentation fosters innovation, as companies strive to differentiate their offerings in a crowded marketplace. The collective influence of these major players shapes the competitive dynamics, as they continuously adapt to emerging trends and consumer needs. In October 2025, Roche Diagnostics (CH) announced the launch of a new liquid biopsy test designed to detect minimal residual disease in hematological malignancies. This strategic move is significant as it positions Roche at the cutting edge of non-invasive testing, potentially increasing patient compliance and expanding its market share. The introduction of this test aligns with the growing trend towards [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937), where tailored treatment plans are based on precise diagnostic information. In September 2025, Abbott Laboratories (US) entered into a collaboration with a leading oncology research institute to develop advanced biomarkers for minimal residual disease detection. This partnership is crucial as it not only enhances Abbott's research capabilities but also accelerates the development of innovative testing solutions. By aligning with academic institutions, Abbott is likely to strengthen its position in the market and foster a culture of innovation that could lead to breakthrough discoveries. In August 2025, Thermo Fisher Scientific (US) unveiled a new cloud-based platform that integrates artificial intelligence into its testing workflows. This platform aims to streamline data analysis and improve the accuracy of minimal residual disease assessments. The strategic importance of this development lies in its potential to enhance operational efficiency and provide healthcare professionals with actionable insights, thereby improving patient outcomes. As AI continues to permeate the healthcare sector, Thermo Fisher's initiative may set a benchmark for future innovations in the industry. As of November 2025, current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and expanding market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized healthcare solutions. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the minimal residual-disease-testing market. ## Recent News & Developments The US Minimal Residual Disease Testing Market has seen significant activity recently, with growing recognition of the crucial role these tests play in monitoring cancer treatment effectiveness. Notably, in August 2023, Illumina announced expanded collaborations to enhance genetic testing capabilities, potentially influencing Minimal Residual Disease diagnostics. Similarly, Exact Sciences has made strides in developing more accurate testing methodologies, addressing the demand for precision in cancer care. In November 2022, Abbott Laboratories launched a new blood test geared toward minimal residual disease, which is anticipated to impact patient management decisions significantly. Mergers and acquisitions have also been pivotal, particularly Takeda Pharmaceutical's acquisition of a smaller biotech firm in June 2023, aiming to bolster its testing portfolio related to oncology. The market is benefiting from a substantial valuation growth trend, with major companies like Thermo Fisher Scientific and F. Hoffmann-La Roche investing heavily in Research and Development for advanced testing solutions. Over the past couple of years, from ongoing regulatory approvals to innovative partnerships, the landscape of the US Minimal Residual Disease Testing Market has evolved rapidly, highlighting the importance of continuous advancements in technology and collaboration among industry leaders. ## Report Scope | MARKET SIZE 2024 | 507.48(USD Million) | | --- | --- | | MARKET SIZE 2025 | 565.13(USD Million) | | MARKET SIZE 2035 | 1657.77(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.36% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche Diagnostics (CH), Abbott Laboratories (US), Thermo Fisher Scientific (US), Qiagen N.V. (NL), Bristol-Myers Squibb (US), Amgen Inc. (US), Illumina Inc. (US), Myriad Genetics Inc. (US) | | Segments Covered | Technology, Application, End User | | Key Market Opportunities | Advancements in liquid biopsy technologies enhance detection capabilities in the minimal residual-disease-testing market. | | Key Market Dynamics | Technological advancements drive innovation in minimal residual disease testing, enhancing accuracy and patient outcomes. | | Countries Covered | US | ## Frequently Asked Questions **Q: What is the current valuation of the US minimal residual-disease-testing market?** A: The market valuation was $507.48 Million in 2024. **Q: What is the projected market size for the US minimal residual-disease-testing market by 2035?** A: The market is projected to reach $1,657.77 Million by 2035. **Q: What is the expected CAGR for the US minimal residual-disease-testing market during the forecast period 2025 - 2035?** A: The expected CAGR is 11.36% during the forecast period. **Q: Which technology segments are leading in the US minimal residual-disease-testing market?** A: The leading technology segments include Next-generation Sequencing (NGS) with a valuation of $650.0 Million by 2035. **Q: How does the Flow Cytometry segment perform in the US minimal residual-disease-testing market?** A: Flow Cytometry is projected to grow from $80.0 Million to $250.0 Million by 2035. **Q: What applications dominate the US minimal residual-disease-testing market?** A: Solid Tumors is expected to dominate with a valuation of $650.0 Million by 2035. **Q: What are the key end-user segments in the US minimal residual-disease-testing market?** A: Diagnostic Laboratories are projected to grow from $250.0 Million to $850.0 Million by 2035. **Q: Who are the major players in the US minimal residual-disease-testing market?** A: Key players include Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific. **Q: What is the market performance of the Leukemia application segment?** A: The Leukemia segment is expected to grow from $150.0 Million to $500.0 Million by 2035. **Q: What is the valuation of the Others segment in the Technology category?** A: The Others segment is projected to grow from $77.48 Million to $257.77 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-minimal-residual-disease-testing-market-16751*